Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14365233 | 0.92 | FFAR4 (0.40) | FFAR4HTR2AHSD11B1PTGDRHTR1A | |
| SCHEMBL4510197 | 0.90 | OPRM1 (0.39) | FFAR4HTR2AHSD11B1HTR1ASLC6A4 | |
| SCHEMBL13674485 | 0.90 | OPRM1 (0.39) | FFAR4HTR2AHSD11B1HTR1ASLC6A4 | |
| SCHEMBL4523794 | 0.88 | HPGD (0.39) | FFAR4HTR2AHSD11B1 | |
| SCHEMBL4509399 | 0.88 | MCL1 (0.39) | FFAR4HSD11B1PTGDR | |
| SCHEMBL4512718 | 0.86 | ALDH1A1 (0.36) | HSD11B1 | |
| SCHEMBL4505225 | 0.86 | HSP90AA1 (0.39) | HSD11B1HTR1ASLC6A4 | |
| SCHEMBL4525933 | 0.86 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL4514955 | 0.86 | S1PR1 (0.40) | FFAR4HSD11B1HTR1ASLC6A4 | |
| SCHEMBL13674510 | 0.85 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | FFAR4 1012/4885HTR2A 4228/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.